Author/Authors :
El-Karaksy, H. University of Cairo - Department of Paediatrics, Egypt , El-Sayed, R. University of Cairo - Department of Paediatrics, Egypt , El-Raziky, M. University of Cairo - Department of Paediatrics, Egypt , El-Koofy, N. University of Cairo - Department of Paediatrics, Egypt , Mansour, S. University of Cairo - Department of Paediatrics, Egypt
Abstract :
The aim of the study was to determine the prevalence of anti-hepatitis A virus (anti-HAV) antibodies among 172 children with chronic liver disease, and to calculate the cost–effectiveness of prescreening prior to hepatitis A vaccination. Anti-HAV antibodies were positive in 85.1%. However, seroprevalence of anti-HAV antibodies was 62.1% in children 5 years and 94.4% in children 5+ years. We conclude that while it is cost-effective to do prescreening before hepatitis A vaccination for children with chronic liver disease aged 5+ years, prescreening might not be cost-effective in those aged 5 years.
